Keyphrases
Phase I Study
100%
Capecitabine
100%
Breast Carcinoma
100%
Brain Metastases
100%
Temozolomide
100%
Antitumor Activity
33%
Breast Cancer
16%
Maximum Tolerated Dose
16%
Stable Disease
16%
Chemotherapy Regimen
16%
Nausea
16%
Newly Diagnosed
16%
Partial Response
16%
Duration of Response
16%
Disease Progression
16%
Single Institution
16%
Dose Level
16%
Objective Response Rate
16%
Time to Progression
16%
Median Time
16%
Prior Chemotherapy
16%
Safety Profile
16%
Whole Brain Radiation Therapy
16%
Phase I Clinical Trial
16%
Supratentorial
16%
Chemotherapy-naïve
16%
Infratentorial
16%
Neurocognitive Function
16%
Multiple Brain Lesions
16%
Pharmacology, Toxicology and Pharmaceutical Science
Capecitabine
100%
Temozolomide
100%
Brain Metastasis
100%
Breast Carcinoma
100%
Antitumor Activity
33%
Chemotherapy
33%
Diseases
16%
Maximum Tolerated Dose
16%
Clinical Trial
16%
Breast Cancer
16%
Nausea
16%
Disease Exacerbation
16%
Patient History of Chemotherapy
16%
Medicine and Dentistry
Breast Carcinoma
100%
Capecitabine
100%
Temozolomide
100%
Brain Metastasis
100%
Antineoplastic Activity
33%
Diseases
16%
Breast Cancer
16%
Clinical Trial
16%
Chemotherapy
16%
Nausea
16%
Disease Exacerbation
16%
Patient History of Chemotherapy
16%
Whole Brain Radiotherapy
16%